Tornier NV VP Stephan Epinette Sells 2,500 Shares (TRNX)
Tornier NV (NASDAQ:TRNX) VP Stephan Epinette unloaded 2,500 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $22.00, for a total transaction of $55,000.00. Following the completion of the transaction, the vice president now directly owns 35,310 shares in the company, valued at approximately $776,820. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Tornier NV (NASDAQ:TRNX) traded down 2.15% on Friday, hitting $21.39. The stock had a trading volume of 85,088 shares. Tornier NV has a 1-year low of $15.17 and a 1-year high of $24.35. The stock has a 50-day moving average of $21.93 and a 200-day moving average of $20.62. The company’s market cap is $1.046 billion.
Tornier NV (NASDAQ:TRNX) last released its earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter last year, the company posted ($0.28) earnings per share. Tornier NV’s revenue was up 11.2% compared to the same quarter last year. Analysts expect that Tornier NV will post $-0.54 EPS for the current fiscal year.
TRNX has been the subject of a number of recent research reports. Analysts at Piper Jaffray raised their price target on shares of Tornier NV from $25.00 to $26.00 in a research note on Friday, August 8th. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Tornier NV from $20.00 to $23.00 in a research note on Friday, August 8th. Finally, analysts at Barclays raised their price target on shares of Tornier NV from $26.00 to $28.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Tornier NV has a consensus rating of “Hold” and an average price target of $22.67.
Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.